Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors

A securities class action alleges Aardvark Therapeutics misrepresented the safety and prospects of ARD-101, its Phase 3 candidate for hyperphagia in Prader-Willi syndrome. Aardvark paused the HERO Phase 3 trial after reversible cardiac observations at above-target doses, triggering a 56.2% share-price decline to $5.47 on March 2, 2026; the FDA subsequently imposed a full clinical hold, followed by a further 32.1% decline to $4.57 on May 15. Shares remain well below the February 2025 IPO price of $16.00, while investors have until October 13, 2026 to seek lead-plaintiff status.

Analysis

The litigation notice is not itself a new fundamental catalyst; the investable issue remains the FDA hold and whether AARD can generate a credible cardiac-safety remediation path. A securities suit can increase D&O costs and management distraction, but damages are unlikely to be material relative to the value destruction already driven by the clinical hold. The more important near-term effect is that it reinforces a damaged credibility discount, limiting the company’s ability to finance on acceptable terms before regulatory clarity.

AARD is effectively a binary, cash-burn clinical asset rather than a conventional operating short. Over the next 1-3 months, monitor FDA correspondence, any disclosed dose-response or ECG/QTc detail, cash runway, and an explicit restart protocol; absent these, valuation should gravitate toward cash less expected burn and wind-down risk. A restart is not sufficient by itself: the market will require evidence that the therapeutic window supports commercially viable dosing, since dose reduction could impair efficacy and sharply reduce the program’s risk-adjusted value.

The contrarian case is that the equity may already embed a prolonged hold or program failure, making fresh shorts unattractive after the existing drawdown. However, small-float biotech liquidity and any financing need create asymmetric downside if management discloses that additional preclinical work, a new healthy-volunteer study, or a reformulation is required. There is no clear read-through to broad obesity names such as LLY or NVO: a gut-restricted hunger-targeting mechanism in a rare-disease population is too differentiated to alter their competitive outlook.

For 6-18 months, the key structural question is financing dilution. If the company cannot restart promptly, fixed corporate costs and trial-restart expenditures can force an equity raise at a depressed price; that outcome is more damaging to residual equity than the lawsuit. Thesis is falsified by a prompt FDA release from hold accompanied by clean cardiac data, a defined restart timeline, and sufficient cash to reach a meaningful clinical milestone without raising capital.

Key Decisions for Investors

• Do not initiate a directional position solely on the class-action announcement; treat it as a sentiment and financing-overhang confirmation, not independent evidence of liability or additional safety deterioration.
• Maintain or initiate a small tactical AARD short only on liquidity-driven rallies of 20%+ without new FDA clearance or disclosed cardiac data; target a return toward cash-value assessment over 1-3 months, with a hard stop on FDA hold release or a fully funded restart plan.
• For existing AARD longs, reduce exposure unless position sizing explicitly assumes a 12+ month hold and future dilution. Reassess immediately upon quarterly cash-runway disclosure; a runway below 12 months without committed capital materially worsens expected equity value.
• Set event alerts for FDA hold resolution, protocol amendments, QTc/arrhythmia data, and capital raises. A hold release with dose-limiting efficacy uncertainty is not a buy signal; require evidence that the revised dose can preserve efficacy before underwriting upside.